Trump Administration Aims to Boost Domestic Production of Generic Drugs
The Trump administration is seeking input from pharmaceutical companies on how to increase domestic manufacturing for 86 essential generic medications, which are currently largely produced overseas. The Office of Management and Budget (OMB) will solicit proposals aimed at shifting the production of these drugs back to the United States. This initiative aligns with broader efforts by the administration to reduce reliance on foreign drug supplies and enhance national security in critical healthcare sectors. Generic drugs account for nearly 90% of prescriptions filled in the U.S., but many are manufactured abroad, raising concerns about supply chain vulnerabilities. The move could impact pharmaceutical companies both domestically and internationally as they may need to adjust production strategies or invest in new domestic facilities.
Topics: domestic manufacturing government regulation pharmaceuticals